Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis

PURPOSE: The survival benefit from gemcitabine plus erlotinib was on average marginal for advanced pancreatic cancer (APC) patients. Skin rash developed shortly after starting treatment seemed to be associated with better efficacy and might be used to assist clinical decision-making, but the results...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Minyan, Feng, Qi, Lu, Ming, Zhou, Jun, Yang, Zuyao, Tang, Jinling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188168/
https://www.ncbi.nlm.nih.gov/pubmed/30349297
http://dx.doi.org/10.2147/OTT.S168418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188168/
https://www.ncbi.nlm.nih.gov/pubmed/30349297
http://dx.doi.org/10.2147/OTT.S168418

Ejemplares similares